

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

August 19, 2025

Gregory Weaver Chief Financial Officer Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, MD 20878

Re: Altimmune, Inc.

Form 10-K for the Fiscal Year Ended December 31, 2024

File No. 001-32587

Dear Gregory Weaver:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences